Alnylam Pharmaceuticals (ALNY) Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, community ranking, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Do institutionals and insiders hold more shares of ALNY or AMGN?

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 0.8% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility and risk, ALNY or AMGN?

Alnylam Pharmaceuticals has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Does the media favor ALNY or AMGN?

In the previous week, Amgen had 34 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 56 mentions for Amgen and 22 mentions for Alnylam Pharmaceuticals. Amgen's average media sentiment score of 1.32 beat Alnylam Pharmaceuticals' score of 1.02 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amgen	45 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer ALNY or AMGN?

Alnylam Pharmaceuticals presently has a consensus target price of $319.17, suggesting a potential upside of 6.89%. Amgen has a consensus target price of $309.22, suggesting a potential upside of 5.97%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.77
Amgen	2 Sell rating(s)	12 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.38

Which has preferable earnings & valuation, ALNY or AMGN?

Amgen has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$2.35B	16.58	-$278.16M	-$2.09	-142.86
Amgen	$34.13B	4.60	$4.09B	$10.96	26.63

Is ALNY or AMGN more profitable?

Amgen has a net margin of 12.24% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Amgen's return on equity of 176.32% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-12.37%	N/A	-6.83%
Amgen	12.24%	176.32%	11.71%

Does the MarketBeat Community prefer ALNY or AMGN?

Amgen received 392 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.32% of users gave Alnylam Pharmaceuticals an outperform vote while only 71.71% of users gave Amgen an outperform vote.

Company	Underperform	Outperform
Alnylam Pharmaceuticals	Outperform Votes 1167 76.32%	Underperform Votes 362 23.68%
Amgen	Outperform Votes 1559 71.71%	Underperform Votes 615 28.29%

Summary

Amgen beats Alnylam Pharmaceuticals on 12 of the 19 factors compared between the two stocks.